finasteride / Generic mfg. - LARVOL DELTA

Electrospun Integrated Janus Nanofibers for Asynchronous Delivery of Finasteride and Tibetan Medicine. (PubMed, Pharmaceutics) - " The present Janus nanostructure system, fabricated via a facile co-shell solvent electrospinning process, has the potential to enable the concurrent yet asynchronous delivery of FIN and JZ herbal components within a single nano-dosage form. This conceptual advance expands the toolkit for designing combination nanomedicines, allowing independent modulation of release kinetics for individual drugs to maximize prospective joint efficacy."

Journal

Lycopus lucidus Extract Attenuates Testosterone Propionate-Induced Benign Prostatic Hyperplasia in Rats. (PubMed, Pharmaceuticals (Basel)) - " LLE (200 mg/kg) significantly reduced prostate weight and prostate index and improved histological alterations, comparable to finasteride... LLE attenuated TP-induced prostatic hyperplasia in rats, suggesting that modulation of androgen metabolism may contribute to its anti-hyperplastic effects. These findings support further investigation of L. lucidus extract in BPH."

IO biomarker • Journal • Preclinical • Benign Prostatic Hyperplasia • Geriatric Disorders • BAX • BCL2

Androgenetic alopecia drugs and male infertility: Evidence from pharmacovigilance and testicular transcriptomics. (PubMed, PLoS One) - "This study systematically evaluated associations between AGA drugs and male infertility using real-world pharmacovigilance data and integrated bioinformatic analyses. The HIF1A-related transcriptomic findings provide a hypothesis-generating biological context for male infertility but do not establish a shared or drug-specific mechanism linking the three medications to infertility. The pharmacovigilance findings indicate reporting signals rather than incidence or causality."

Adverse events • Journal • Alopecia • Immunology • Infertility • Sexual Disorders • FGF • HIF1A

A Prospective, Randomized Controlled Clinical Trial of Finasteride Combined with Testosterone Undecanoate and Anastrozole in the Treatment of Benign Prostatic Hyperplasia (ChiCTR) - P2 | N=214 | Recruiting | Sponsor: Affiliated Hospital of Zunyi Medical University; Affiliated Hospital of Zunyi Medical University

New P2 trial • Benign Prostatic Hyperplasia

Editorial Comment on "Endoscopic Outlet Surgery vs Medical Therapy for Benign Prostatic Hyperplasia: Impact on Incident Mood Disorders" and "Safety and Efficacy of Prostatic Urethral Lift for Lower Urinary Tract Symptoms in Men with a History of Prostate Radiation. (PubMed, Urology) - No abstract available

Journal • Benign Prostatic Hyperplasia • CNS Disorders • Psychiatry

Oral medications for hair loss in the elderly (EADV 2026) - "This includes low-dose oral minoxidil, finasteride, dutasteride, spironolactone, hydroxychloroquine and JAK inhibitors. Learning Objectives After this presentation, participants should be able to: Select suitable oral treatments for androgenetic alopecia, frontal fibrosing alopecia and alopecia areata.Assess cardiovascular, renal, thrombotic, infectious and oncological risks before treatment. Apply recent recommendations on low-dose oral minoxidil and JAK inhibitors."

Clinical • Alopecia • Cardiovascular • Fibrosis • Immunology • Infectious Disease • Lichen Planus • Nephrology • Renal Disease • Thrombosis

Testosterone Promotes NSCLC Metastasis via the FGF21/AKT/mTOR Signaling Axis (IASLC-WCLC 2026) - "Pharmacological inhibition of androgen signaling with finasteride suppresses this pathway, suggesting a potential therapeutic strategy. These findings provide mechanistic insights and support targeting androgen-related pathways in NSCLC metastasis."

Lung Cancer • Non Small Cell Lung Cancer • Solid Tumor • FGF21

Hair Growth-Supporting and Follicle-Protective Potential of a Botanical-Based Supplement Ingredient: In Vitro, Ex Vivo, and Molecular Docking Studies. (PubMed, Biomolecules) - "Molecular docking (AutoDock Vina) of the main Elissara bioactives (oleuropein, hydroxytyrosol, verbascoside, carnosic acid, carnosol, and quercetin) identified SRD5A2 as a favorable predicted target, with individual binding energies ranging from -8.70 to -9.73 kcal/mol, approaching finasteride/dutasteride reference values. Together, these findings support the potential of Elissara as a promising nutricosmetic ingredient for supporting follicular resilience through multiple follicle-relevant pathways. Clinical studies assessing hair growth outcomes are needed to determine whether these preclinical findings translate into measurable benefits."

IO biomarker • Journal • Preclinical • BCL2 • IGF1 • SRD5A2

THE ASSOCIATION BETWEEN 5-ALPHA REDUCTASE INHIBITORS AND PROSTATE CANCER MORTALITY (AUA 2024) - "Funded by Canadian Urological Association Scholarship Fund INTRODUCTION AND OBJECTIVE: 5-alpha-reductase-inhibitors (5-ARIs), finasteride and dutasteride, are approved for treating benign prostatic hyperplasia (BPH), and reduce prostate cancer risk by 25%...Cox proportional hazard models with inverse probability treatment weights (IPTW) were used adjusting for prognostic covariates (age, income quintile, rurality, stage, morphology type, laterality, PSA, total Gleason score, total number of positive cores, maximum percent core, primary treatment, prior statin, post-treatment statin, prior metformin, post-treatment metformin)... In our large population-based study, pre-diagnostic 5-ARI use was not associated with PCa-specific mortality or all-cause mortality. These data offer reassuring safety data for patients using 5-ARI for both benign and chemopreventive reasons."

Benign Prostatic Hyperplasia • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Urology

The Association of 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia with Development of Male Breast Disease and Erectile Dysfunction: A Retrospective Cohort Study of TriNetX Database. (PubMed, Urology) - "In this multi-institutional retrospective cohort study, we did not find an increased risk of MBC associated with 5ARI use."

Journal • Retrospective data • Benign Prostatic Hyperplasia • Breast Cancer • Erectile Dysfunction • Male Breast Cancer • Oncology • Solid Tumor

Development of a human hair follicle organoid platform: Initial feasibility and optimization strategy | Poster Board #1395 (ACS-Fall 2026) - "Although current therapies such as finasteride and minoxidil show efficacy, their benefits are frequently limited by adverse effects or poor long-term durability. Following the identification of top hits from our screen, we will perform pathway enrichment network analyses and downstream functional studies to define relationships between kinase and androgen signaling. This study is expected to identify kinase pathways critical for HF homeostasis and androgen-mediated pathology, providing a mechanistically grounded framework for AA biology."

Alopecia • Immunology

A retrospective cohort study on the improvement of urodynamic parameters and NIH-CPSI scores with Relin granules in BPH patients with high prostatitis-like symptom scores. (PubMed, Am J Transl Res) - "In BPH patients with high prostatitis-like symptoms, adding Relin Granules to conventional therapy was associated with alleviation of pain, improvement in quality of life and lower urinary tract symptoms (LUTS), potentially through anti-inflammatory mechanisms, with good safety."

Journal • Retrospective data • Benign Prostatic Hyperplasia • Inflammation • Oncology • Pain • IL10 • TNFA

No Evidence of Post-Finasteride Syndrome in 267,983 person-years follow-up in the Prostate Cancer Prevention Trial. (PubMed, Urology) - "In the largest placebo-controlled study of the five-alpha reductase inhibitor, finasteride, long-term follow-up does not support the concept of a 'Post-Finasteride Syndrome'. The anecdotal reports to date are likely related to the ubiquitous nature of these symptoms in an aging population and reporting bias."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Sleep Apnea in Elderly (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: VA Office of Research and Development | Trial completion date: Jul 2026 ➔ Dec 2027 | Trial primary completion date: Jul 2026 ➔ Jul 2027

Trial completion date • Trial primary completion date • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Apnea • Sleep Disorder

Diet-Induced Obesity Promotes Alopecia Through Oxidative Stress and Androgen Signalling in Female Mice. (PubMed, Exp Dermatol) - "In the second experiment, 8-week-old female mice were assigned to four groups (n = 6/group): HFD with N-acetylcysteine (NAC), finasteride, spironolactone, or vehicle administered by oral gavage for 12 weeks. HFD-induced obesity exacerbates hair loss in female mice by enhancing oxidative stress and activating androgen signalling in the skin. Targeting these pathways, such as antioxidants and antiandrogens, may mitigate HFD-accelerated hair loss."

Journal • Preclinical • Alopecia • Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Immunology • Obesity • Polyendocrine Metabolic Ovarian Syndrome

SAFETY OF TAMSULOSIN ALONE OR IN COMBINATION WITH 5Α-REDUCTASE INHIBITORS ON LIPID PROFILE, RENAL FUNCTION, AND LIVER PARAMETERS. (PubMed, Georgian Med News) - "Tamsulosin administered alone or in combination with finasteride or dutasteride for more than three months demonstrated non-significant differences in the measured biochemical parameters among the studied groups represented by no adverse effects on lipid metabolism, renal function, liver enzymes, or bilirubin homeostasis. These findings support the safe use of these therapeutic regimens in elderly BPH patients, including those with underlying metabolic or organ function concerns. Further prospective longitudinal studies with larger sample sizes are warranted to confirm these observations."

Journal • Benign Prostatic Hyperplasia • Metabolic Disorders

Optimization and Characterization of TSG-Enriched Polygonum multiflorum Extract and Its Dual Mechanism Against Androgenetic Alopecia via 5α-Reductase Inhibition and Wnt/β-Catenin Activation. (PubMed, Int J Mol Sci) - "PME exhibited potent dose-dependent inhibition of 5α-reductase activity, reaching 92.7% inhibition at 1 μg/mL, comparable to that of finasteride...Consequently, the expression of hair growth-related proteins, including Ki67 (1.98-fold), epidermal growth factor (EGF, 1.54-fold), insulin-like growth factor-1 (IGF-1, 1.21-fold), and vascular endothelial growth factor (VEGF, 1.34-fold), was significantly upregulated. These findings demonstrate, for the first time, that TSG-enriched PME obtained through optimized MAE and chromatographic purification promotes hair regeneration through a dual mechanism involving 5α-reductase inhibition and Wnt/β-catenin activation, highlighting its potential as a natural therapeutic candidate for androgenetic alopecia."

Journal • Alopecia • Immunology • IGF1

Progress in the Application of Exosomes in Androgenetic Alopecia: Focusing on Molecular Mechanisms. (PubMed, Int J Nanomedicine) - "Currently, FDA-approved drugs for AGA treatment, minoxidil and finasteride, cannot provide satisfactory outcomes for all patients and can sometimes cause side effects. This review summarizes the preclinical and clinical progress in exosome-based therapies for AGA treatment, with a particular focus on their molecular mechanisms, especially their regulation of key signaling pathways involved in AGA pathogenesis, such as Wnt/β-catenin, Shh, TGF-β/Smad, PI3K/AKT, and MAPK signaling pathways. These endeavors are expected to provide researchers with valuable scientific insights and practical information for AGA drug discovery."

Journal • Review • Alopecia • Immunology • CTNNB1 • TGFB1

Incidence of type 2 diabetes mellitus in men receiving finasteride and tamsulosin: a cross-validation cohort study using data from China and UK populations. (PubMed, Diabetes Res Clin Pract) - "These findings suggest potential benefits of tamsulosin against T2DM and underscore the need for careful monitoring of T2DM risk in finasteride users."

Journal • Benign Prostatic Hyperplasia • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus

Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial (clinicaltrials.gov) - P2/3 | N=300 | Not yet recruiting | Sponsor: VA Office of Research and Development

New P2/3 trial • CNS Disorders • Endocrine Disorders • Musculoskeletal Diseases • Orthopedics

Concurrent Jackstone Calculus and Prostate Cancer: Should They Be Treated Concurrently or Sequentially? (PubMed, Am J Mens Health) - "We report a 70-year-old man with 1 year of progressive dysuria and intermittent interruption of urinary stream despite tamsulosin and finasteride. In men with lower urinary tract symptoms and abnormal prostate-specific antigen values, bladder outlet obstruction, infection, or bladder stones should not preclude further oncologic evaluation. In selected patients in whom definitive prostate surgery is chosen, combined stone removal can be a practical single-stage approach."

Journal • Genito-urinary Cancer • Infectious Disease • Nephrology • Oncology • Prostate Cancer • Solid Tumor • Urolithiasis

Finasteride and Cutibacterium (clinicaltrials.gov) - P4 | N=40 | Not yet recruiting | Sponsor: University of Washington

New P4 trial • Infectious Disease

Response to: "finasteride prescribed for hair loss consistently leads to depression". (PubMed, Postgrad Med) - No abstract available

Journal • Alopecia • CNS Disorders • Depression • Mood Disorders • Psychiatry

Finasteride prescribed for hair loss consistently leads to depression. Comment on 'Depression risk of 5-alpha reductase inhibitors: impact of active-comparator versus non-drug user control groups on risk measurement'. (PubMed, Postgrad Med) - No abstract available

Journal • Alopecia • CNS Disorders • Depression • Immunology • Mood Disorders • Psychiatry

Steroid 5α-reductases in the brain: From neurosteroidogenesis to therapeutic implications. (PubMed, Front Neuroendocrinol) - "These advances may provide a framework for understanding the complex neurobehavioral profile of 5αR inhibitors such as finasteride and dutasteride. In this comprehensive review, we synthesize pharmacological, genetic, and behavioral evidence on the distinct contributions of 5αR1 and 5αR2 to steroid signaling across stress, sex, and development. Finally, we outline several open questions in the biology of 5αRs, the resolution of which will be essential to advancing toward mechanistically precise and clinically actionable interventions."

Journal • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry • Sexual Disorders • Tic Disorders • Tourette Syndrome • SRD5A3